Home Online Features VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model
VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model
Press Releases
VelaVigo Cayman Limited  
April 18, 2025

VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model

SHANGHAI and BOSTON, April 17, 2025 /PRNewswire/ -- VelaVigo Bio, the U.S. subsidiary of VelaVigo Cayman Limited (VelaVigo), a biotech company with a robust discovery and development platform of multi-specific

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social